Skip to content
+91-79-4107-8000
info@lincolnpharma.com
Facebook page opens in new window
X page opens in new window
Instagram page opens in new window
Linkedin page opens in new window
YouTube page opens in new window
Search:
Africa Site
Lincoln Pharmaceuticals
Healthcare for All
Home
About Us
Operations
Domestic
Operations
Products
Divisions
International
Operations
Products
Contact
API
Manufacturing
Capabilities
Certifications
Quality Control & Assurance
EHS Policy
Business Opportunity
Portfolio
Key Brands
Products
New Launches
R & D
Highlights
Infrastructure
Innovation
Collaboration
Acts of Science
Activities
Investors
Careers
Contact
Home
About Us
Operations
Domestic
Operations
Products
Divisions
International
Operations
Products
Contact
API
Manufacturing
Capabilities
Certifications
Quality Control & Assurance
EHS Policy
Business Opportunity
Portfolio
Key Brands
Products
New Launches
R & D
Highlights
Infrastructure
Innovation
Collaboration
Acts of Science
Activities
Investors
Careers
Contact
Details of establishment of Whistle Blower Policy
You are here:
Home
Investors
Disclosures under Regulation 46 of the LODR
Details of establishment of Whistle…
2022-2023
Q1
Q2
Q3
Q4
Q5
2021-2022
Q1
Q2
Q3
Q4
Q5
2020-2021
Q1
Q2
Q3
Q4
Q5
2019-2020
Q1
Q2
Q3
Q4
Q5
2018-2019
Q1
Q2
Q3
Q4
Q5
2017-2018
Q1
Q2
Q3
Q4
Q5
2016-2017
Q1
Q2
Q3
Q4
Q5
2015-2016
Q1
Q2
Q3
Q4
Q5
Go to Top
